BACKGROUND AND PURPOSE: Doxorubicin evokes oxidative stress and precipitates cell apoptosis in testicular tissues. The aim of this study was to investigate whether the Ginkgo biloba extract 761 (EGb), a widely used herbal medicine with potent anti-oxidant and anti-apoptotic properties, could protect testes from such doxorubicin injury. EXPERIMENTAL APPROACH: Sprague-Dawley male rats (8 weeks old) were given vehicle, doxorubicin alone (3 mg kg(-1) every 2 days for three doses), EGb alone (5 mg kg(-1) every 2 days for three doses), or EGb followed by doxorubicin (each dose administered 1 day after EGb). At 7 days after the first drug treatment oxidative and apoptotic testicular toxicity was evaluated by biochemical, histological and flow cytometric analyses. KEY RESULTS: Compared with controls, testes from doxorubicin-treated rats displayed impaired spermatogenesis, depleted haploid germ cell subpopulations, increased lipid peroxidation products (malondialdehyde), depressed antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase and glutathione), reduced antioxidant enzyme expression (superoxide dismutase) and elevated apoptotic indexes (pro-apoptotic modulation of Bcl-2 family proteins, intensification of p53 and Apaf-1, release of mitochondrial cytochrome c, activation of caspase-3 and increase of terminal deoxynucleotidyl transferase nick-end labelling/sub-haploid cells), while EGb pretreatment effectively alleviated all of these doxorubicin-induced abnormalities in testes. CONCLUSIONS AND IMPLICATIONS: These results demonstrate that EGb protected against the oxidative and apoptotic actions of doxorubicin on testes. EGb may be a promising adjuvant therapy medicine, potentially ameliorating testicular toxicity of this anti-neoplastic agent in clinical practice.
BACKGROUND AND PURPOSE:Doxorubicin evokes oxidative stress and precipitates cell apoptosis in testicular tissues. The aim of this study was to investigate whether the Ginkgo biloba extract 761 (EGb), a widely used herbal medicine with potent anti-oxidant and anti-apoptotic properties, could protect testes from such doxorubicininjury. EXPERIMENTAL APPROACH: Sprague-Dawley male rats (8 weeks old) were given vehicle, doxorubicin alone (3 mg kg(-1) every 2 days for three doses), EGb alone (5 mg kg(-1) every 2 days for three doses), or EGb followed by doxorubicin (each dose administered 1 day after EGb). At 7 days after the first drug treatment oxidative and apoptotic testicular toxicity was evaluated by biochemical, histological and flow cytometric analyses. KEY RESULTS: Compared with controls, testes from doxorubicin-treated rats displayed impaired spermatogenesis, depleted haploid germ cell subpopulations, increased lipid peroxidation products (malondialdehyde), depressed antioxidant enzyme activities (superoxide dismutase, glutathione peroxidase and glutathione), reduced antioxidant enzyme expression (superoxide dismutase) and elevated apoptotic indexes (pro-apoptotic modulation of Bcl-2 family proteins, intensification of p53 and Apaf-1, release of mitochondrial cytochrome c, activation of caspase-3 and increase of terminal deoxynucleotidyl transferase nick-end labelling/sub-haploid cells), while EGb pretreatment effectively alleviated all of these doxorubicin-induced abnormalities in testes. CONCLUSIONS AND IMPLICATIONS: These results demonstrate that EGb protected against the oxidative and apoptotic actions of doxorubicin on testes. EGb may be a promising adjuvant therapy medicine, potentially ameliorating testicular toxicity of this anti-neoplastic agent in clinical practice.
Authors: O Timioğlu; S Kutsal; M Ozkur; O Uluoğlu; A Aricioğlu; C Cevik; E Düzgün; B Sancak; A Poyraz Journal: Res Commun Mol Pathol Pharmacol Date: 1999
Authors: Gang Lu; Yan Wu; Ying Tat Mak; Sen Mun Wai; Zhong Tang Feng; John A Rudd; David Tai Wai Yew Journal: Brain Res Date: 2006-05-04 Impact factor: 3.252
Authors: A Lenzi; L Gandini; F Lombardo; M Picardo; V Maresca; E Panfili; F Tramer; C Boitani; F Dondero Journal: Contraception Date: 2002-04 Impact factor: 3.375
Authors: Sandeep K Mallipattu; Sylvia J Horne; Vivette D'Agati; Goutham Narla; Ruijie Liu; Michael A Frohman; Kathleen Dickman; Edward Y Chen; Avi Ma'ayan; Agnieszka B Bialkowska; Amr M Ghaleb; Mandayam O Nandan; Mukesh K Jain; Ilse Daehn; Peter Y Chuang; Vincent W Yang; John C He Journal: J Clin Invest Date: 2015-02-17 Impact factor: 14.808
Authors: Norma Serrano-García; José Pedraza-Chaverri; José Juan Mares-Sámano; Marisol Orozco-Ibarra; Arturo Cruz-Salgado; Anabel Jiménez-Anguiano; Julio Sotelo; Cristina Trejo-Solís Journal: Evid Based Complement Alternat Med Date: 2013-07-29 Impact factor: 2.629